Vericel Secures Up to $197M BARDA Contract for NexoBrid – 10-Year Deal to Bolster U.S. Burn and Blast Injury Preparedness
Vericel won a 10-year, $197M BARDA deal to supply NexoBrid, a burn treatment, and expand its use and production in the U.S.
/ 1659 items
#XY↓
Wedbush Upgrades Arcus Biosciences Ahead of Key 2026 Clinical Data
Wedbush upgraded Arcus Biosciences with a new $41 price target and added the stock to its Best Ideas List ahead of major 2026 clinical updates for casdatifan in kidney cancer.
FDA Fast Track Boosts Context Therapeutics’ CTIM-76 for Hard-to-Treat Ovarian Cancer
Context Therapeutics’ CTIM-76 wins FDA Fast Track Designation for platinum-resistant ovarian cancer. Phase 1a trial ongoing with interim data expected in June 2026.
Immunovant’s Batoclimab Flops in Phase 3 Thyroid Eye Disease Trials
Immunovant’s batoclimab failed key TED trials, but high doses helped; focus now shifts to next-gen drug IMVT-1402 for autoimmune disease.
Cocrystal Pharma Gets FDA Fast Track for Norovirus Treatment & Prevention
FDA fast-tracks a new oral drug, CDI-988, to treat and prevent norovirus—a common stomach virus affecting millions worldwide.
Lipocine’s Oral PPD Pill Shows Strong Promise in Key Group Despite Missing Main Goal
Lipocine’s oral pill for postpartum depression missed main goal but showed fast, lasting benefits in some patients with good safety profile.